Rona Therapeutics, a Shanghai-based platform company that is fully integrated and dedicated to the development, manufacturing, and discovery of RNA therapeutics has closed a $33m Series B financing.
Lilly Asia Ventures, CMB International and Lanting Capital were the backers.
The company plans to use the funds for its proprietary delivery platform, as well as to expand its initial therapeutic pipeline.
Rona Therapeutics, which was established in 2021, is co-founded by Stella SHI (CEO and cofounder). The company aims at developing innovative RNA medicines. It has a proprietary platform to allow therapeutics to have more precise, stable, and longer lasting effects. Its RNA medicines have modular and programable delivery systems that target disease areas such as neurological diseases, metabolic disorders, and ophthalmology. To realize the full potential of powerful RNA therapeutics, the company is expanding its facilities for nucleic acid production, delivery platform, oligonucleotide chemistry modification, RNA biology, and manufacturing capabilities.